Literature DB >> 7817875

Antisense treatment of viral infection.

J L Whitton1.   

Abstract

In this chapter I have attempted to outline the rationale that underlies the antisense approach to treatment of virus infection, to catalog the effector molecules that are currently available, and to estimate the relative worth of each. In so doing I have tried to describe the criteria that might be employed in their design and the factors that may determine their efficacy in tissue culture and, perhaps, in vivo. Finally, I have described the few examples presently available that indicate that antisense approaches may one day be therapeutically useful in treatment of disease of viral or nonviral origin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7817875     DOI: 10.1016/s0065-3527(08)60331-0

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  4 in total

1.  Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis.

Authors:  Q H Nie; Y Q Cheng; Y M Xie; Y X Zhou; Y Z Cao
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  "Hairpin" and "hammerhead" ribozymes directed towards the mumps virus nucleocapsid RNA: specific cleavage of a small synthetic RNA substrate and full-length mRNA.

Authors:  J Albuquerque-Silva; M J De Vos; A Bollen; S Houard
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

3.  Expression of an antisense hla fragment in Staphylococcus aureus reduces alpha-toxin production in vitro and attenuates lethal activity in a murine model.

Authors:  D S Kernodle; R K Voladri; B E Menzies; C C Hager; K M Edwards
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

4.  Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells.

Authors:  J Beck; M Nassal
Journal:  Nucleic Acids Res       Date:  1995-12-25       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.